In addition to Type 2 diabetes, Ozempic is FDA approved to reduce the risk of heart attacks and strokes in people with diabetes and heart disease
Alternative medication classes should be considered if GLP-1 therapy proves intolerable: SGLT2 inhibitors (such as dapagliflozin, empagliflozin) for type 2 diabetes, which work via a completely different mechanism and rarely cause gastrointestinal side effects DPP-4 inhibitors (such as sitagliptin, linagliptin), which enhance endogenous GLP-1 activity more gently Metformin remains first-line for type 2 diabetes, though it can also cause gastrointestinal side effects Orlistat for weight management, though this also has gastrointestinal side effects of a different nature For weight management specifically, NICE recommends a comprehensive approach including dietary modification, increased physical activity, and behavioural interventions, with or without pharmacotherapy
This may involve adjusting your GLP-1 medication
Eli Lilly and Novo Nordisk are pushing back aggressively, filing lawsuits that accuse companies of mass-prescribing compounded versions under the guise of customization
Following the programs success, tirzepatide was approved by the United States Food and Drug Administration (FDA) in 2022 as a treatment for T2D, at doses up to 15mg/weekly under the brand name Mounjaro [1, 5]
Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: evidence from the LEADER trial